Anixa Biosciences

$2.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.13 (-5.99%) Today
+$0.00 (+0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ANIX and other stocks, options, and ETFs commission-free!

About ANIX

Anixa Biosciences, Inc. Common Stock, also called Anixa Biosciences, is a cancer-focused biotechnology company, which focuses on harnessing the body’s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA. The listed name for ANIX is Anixa Biosciences, Inc. Common Stock.

CEO
Amit D. Kumar
Employees
8
Headquarters
San Jose, California
Founded
1982
Market Cap
48.53M
Price-Earnings Ratio
Dividend Yield
Average Volume
104.42K
High Today
$2.22
Low Today
$1.96
Open Price
$2.21
Volume
268.68K
52 Week High
$4.13
52 Week Low
$1.33

Collections

ANIX Earnings

-$0.11
-$0.07
-$0.04
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Jan 7, After Hours

You May Also Like